Cardiome inks commercialization deal with Aspen for Brinavess in South Africa

Both the firms have not been disclosed financial details of the agreement. Aspen has agreed to specific annual commercial goals for Brinavess.

Cardiome chief commercial officer Karim Lalji said: "We are pleased to expand our commercial agreement with Aspen to now include Brinavess in South Africa.

"Aspen has proven to be a valuable partner to Cardiome through their commercialization efforts behind Aggrastat.

"This will be the first country in Africa where Brinavess will be launched and we remain committed to making this drug available to all our customers worldwide."

Cardiome is focused on the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.